Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Update: Moderna’s Variant-Targeting Vaccine Moves Into Trial, J&J Looks Set For US Authorization

Plus: Sanofi/GSK Restart Vaccine Trials

Executive Summary

A round up of COVID-19 developments, also including news on the EMA beginning a rolling review of Celltrion's antibody therapy, and progress for Novavax and Moderna in Japan.

You may also be interested in...



Coronavirus Update: Pfizer/BioNTech Vaccine Shows Six-Month, Variant Protection

The companies still plan to develop a variant-specific version, while J&J said it anticipates meeting vaccine supply goals despite a manufacturing mix-up.

Coronavirus Update: Takeda Contractor To Manufacture J&J Vaccine; Moderna Starts Pediatric Trial

Takeda agreed with its contract manufacturer to grant access to its dengue vaccine production capacity for Johnson & Johnson's COVID-19 vaccine. Frontrunner Moderna started a pediatric trial in children as young as six months. GSK and Medicago began the Phase III portion of a Phase II/III vaccine trial. And China is limiting inbound travel to people vaccinated with China-made vaccines.

Coronavirus Update: What’s The Window For J&J's COVID-19 Vaccine?

A round up of COVID-19 developments, including the CDC advising that it is "prudent" to start testing variant vaccines in case the South African B.1.351 strain gains a foothold in the US.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143876

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel